In an ovarian cancer mouse model, CXCL13 in conjunction with anti-PD-1 therapy resulted in tumor infiltration with CXCR5+CD8+ T cells and improved survival [38], further underscoring the role of CXCL13 as key chemoattractant in ICI-treated cancers. This evidence concerns the gene CD8A and neoplasm.